• Mashup Score: 8

    Integration of mathematical modeling, ecological analyses of patient biopsies, and neoantigen heterogeneity suggests recruitment of immunosuppressive cells is key to initializing transformation from adenoma to carcinoma in human colorectal cancer.

    Tweet Tweets with this article
    • A2-1 📌🔥tumors have lots of immune cells 📌🧊tumors have very little immune cell infiltration Here’s 👇a great model illustrating the origins of CRC. As adenomas progress to carcinomas it becomes less immunogenic & more immunosuppressive. https://t.co/CIHJuGZtk8 #CRCTrialsChat https://t.co/DyLfYVFNGC

  • Mashup Score: 15

    Genomic factors, in particular KRAS and TP53 mutation, may assist in patient selection and radiotherapeutic decision-making for patients with oligometastatic CRC. Prospective validation, ideally with genomic correlation of all irradiated metastases, is warranted.

    Tweet Tweets with this article
    • A8-3 📌Similarly, data suggest that KRAS + TP53 mutation may be associated with poorer local control & Overall Survival after oligometastasis-directed SBRT https://t.co/mThEaDmApb Figure showing local failure #CRCTrialsChat @OncoAlert #CRCSM https://t.co/6phb6WxvRx

    • A8-2 📌Similarly, data suggest that KRAS + TP53 mutation may be associated with poorer local control & Overall Survival after oligometastasis-directed SBRT https://t.co/mThEaDmApb Figure showing OS #CRCTrialsChat @OncoAlert #CRCSM https://t.co/iqkIJZDpse

  • Mashup Score: 1

    We begin the 2023 #CRCTrialsChat with a session on Clinical Trial Basics

    Tweet Tweets with this article
    • RT @CrcTrialsChat: The Wakelet link of yesterday's #CRCTrialsChat is available here: https://t.co/KYkYpFlE28 Thanks to all who stopped by.…

  • Mashup Score: 20

    Author summary Why was this study done? Recurrence risk remains high in patients who underwent curative-intent surgical resection of colorectal cancer liver metastases (CRLM), with limited additional benefit from pre- or postoperative chemotherapy. There is currently no validated biomarker of recurrence for resected CRLM that could help guide the use of chemotherapy for the individual patient….

    Tweet Tweets with this article
    • https://t.co/2G7n792yTL 📌54 pts with resectable CRLM 📌Can post-op ctDNA detect MRD & predict relapse? 📌Value of serial ctDNA during & after chemo? #CRCTrialsChat https://t.co/PjCAv0DCNR

    • https://t.co/2G7n79k9Lj 📌For #CRC pts with resectable liver mets after sx, recurrence risk remains high. Additional benefit from pre-or post-op chemo? 📌No validated biomarker yet 📌ctDNA maybe a promising marker, ctDNA +ve➡️ highly predictive of relapse #CRCTrialsChat https://t.co/RfVZIb2QdC

    • RT @aparna1024: https://t.co/2G7n792yTL 📌54 pts with resectable CRLM 📌Can post-op ctDNA detect MRD & predict relapse? 📌Value of serial ctDN…

    • RT @aparna1024: https://t.co/2G7n79k9Lj 📌For #CRC pts with resectable liver mets after sx, recurrence risk remains high. Additional benefit…